DIRS.INFO The most relevant business & tech news

☆ Novavax says Omicron shot shows strong immune response as second booster
▼ + stars: | 2022-11-08 | by ( ) www.reuters.com time to read: +2 min

Nov 8 (Reuters) - Vaccine maker Novavax Inc (NVAX.O) said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study. Data showed the shot, NVX-CoV2515, produced 1.6 times the amount of neutralizing antibodies in people who had previously not been exposed to COVID-19 compared to Novavax's original coronavirus vaccine. The trial included Novavax's so-called bivalent vaccine, the BA.1-tailored shot and its prototype vaccine. Novavax says the results from the study showed its Omicron-tailored shot can be changed to target a new variant vaccine if necessary. Novavax's COVID shot has not yet received approval in the United States as a second booster dose.

☆ Pfizer, BioNTech start COVID-flu combination vaccine study
▼ + stars: | 2022-11-03 | by ( ) www.reuters.com time to read: +1 min

Nov 3 (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N) and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday. The single-dose vaccine candidate is a combination of Pfizer's mRNA-based flu shot and the companies' Omicron-tailored COVID-19 booster shot. The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot's safety, tolerability and immunogenicity, or the ability to generate immune response. Rivals Moderna Inc (MRNA.O) and Novavax Inc (NVAX.O) are also developing combination vaccines targeting both COVID-19 and influenza. read moreReporting by Bhanvi Satija in Bengaluru; Editing by Savio D'Souza and Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion, and said new deals and drugs in development should help replace future declining vaccine sales and lost revenue from patent expirations. Sales of the Pfizer/BioNTech COVID vaccine are down from pandemic highs as many countries have neared the end of their primary vaccination campaigns. Third-quarter sales of the COVID vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion. However, $7.51 billion in sales of Paxlovid, the company's COVID-19 antiviral treatment, fell short of estimates of $7.66 billion. Pfizer reported adjusted earnings of $1.78 per share in the third quarter, beating analysts' estimates by 39 cents.

☆ Pfizer boosts COVID vaccine sales forecast by $2 bln
▼ + stars: | 2022-11-01 | by ( Manas Mishra | ) www.reuters.com time to read: +2 min

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations. The U.S. drugmaker's shares rose 2.4% to $447.67 in morning trading as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine. The upbeat earnings also sent shares of rival COVID-19 vaccine makers higher. Sales of the COVID-19 vaccine have eased from pandemic highs on soft demand for the original shots, sparking concerns over demand over the next few years. Third-quarter sales of the COVID-19 vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion.

☆ Pfizer COVID vaccine price hike seen giving revenue boost for years
▼ + stars: | 2022-10-21 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

Oct 21 (Reuters) - Pfizer's plan to as much as quadruple current U.S. prices for its COVID-19 vaccines going forward could spur revenue for years, analysts said. Outside the United States, Pfizer said it already has contracts with governments in many developed markets that extend through 2023 with prices that have already been set. Moderna had previously suggested commercial price expectations in a range of $64 to $100 a shot. Wall Street was expecting such price hikes due to weak demand for COVID vaccines, which meant manufacturers would need to hike prices to meet revenue forecasts for 2023 and beyond. Around 19.4 million people in the United States received the updated booster over the first seven weeks of its rollout.

☆ Analysis: Falling demand for COVID boosters puts price hikes on the table
▼ + stars: | 2022-10-20 | by ( Michael Erman | ) www.reuters.com time to read: +5 min

Last year, many on Wall Street were estimating the number of COVID-19 shots would be in line with the annual flu vaccine, which is the vaccine market leader with more than 160 million shots per year in the United States and 600 million shots globally. A recent poll by Kaiser Family Foundation found that two-thirds of American adults do not plan on getting a COVID vaccine soon. He added that instances of COVID infections in those who have been vaccinated has left many to question the effectiveness of the vaccine. The companies could make up for some of the weaker demand with price increases. That would mean annual revenue of $3 billion to $5 billion over the long-term for a company like Moderna, he added.

☆ Cramer's lightning round: State Street is a buy
▼ + stars: | 2022-10-20 | by ( Krystal Hur | ) www.cnbc.com time to read: 1 min

Loading chart...State Street Corp : "I think State Street down here at this level is a terrific buy." Loading chart...Fox Corp. Class B : "I don't like the media stocks. The media stocks I do like are Google , Meta and Amazon ." Loading chart...Generac Holdings : "I do not want to touch this one." Disclaimer: Cramer's Charitable Trust owns shares of Alphabet, Meta and Amazon.

☆ U.S. FDA authorizes Novavax's COVID vaccine as booster for adults
▼ + stars: | 2022-10-19 | by ( Nancy Lapid | ) www.reuters.com time to read: +1 min

Oct 19 (Reuters) - The U.S. Food and Drug Administration on Wednesday authorized Novavax Inc's (NVAX.O) COVID-19 vaccine as a booster for adults. The booster authorization applies to people who are unable to get updated Omicron-tailored boosters, or those who would choose not to receive any other booster dose of a vaccine. The regulator's decision is in addition to the earlier clearance for the vaccine as a primary two-shot regimen for those 12 years and above. The company, however, has been struggling with sales of the vaccine and in August had halved its full-year revenue forecast, saying it does not expect further sales of its COVID-19 shot in the United States this year. read moreRegister now for FREE unlimited access to Reuters.com RegisterReporting by Leroy Leo in Bengaluru; Editing by Anil D'SilvaOur Standards: The Thomson Reuters Trust Principles.

☆ Novavax says COVID booster dose shows benefit against Omicron variants
▼ + stars: | 2022-10-12 | by ( ) www.reuters.com time to read: +1 min

Oct 12 (Reuters) - Novavax Inc (NVAX.O) said on Wednesday data from studies in adults and adolescents showed that the booster dose of its COVID vaccine produced robust antibodies against several Omicron variants, including BA.1, BA.2 and BA.5. The data was from two studies - a late-stage study evaluating the booster in adults and adolescents who had received Novavax primary vaccination and another study testing it in those aged 18 to 49 who had received primary series of Novavax vaccine or other authorized or approved vaccines. In the late-stage study, a single homologous booster dose significantly increased antibody levels against these variants relative to pre-boost levels, the company said. "These data are an early indication that our vaccine may be effective against variants such as Omicron," Novavax executive Gregory M. Glenn said. The company said ongoing trials are studying the efficacy of the vaccine against variants including BA.4 and BA.5.

☆ Cramer's lightning round: BlackBerry is not a buy
▼ + stars: | 2022-10-10 | by ( Krystal Hur | ) www.cnbc.com time to read: 1 min

Loading chart...Moody's Corp : "They're such a good company, but there's been so little issuance for them to rate to begin with." Loading chart...BlackBerry : "I've been against them the whole way down. They're losing money." Loading chart...Novavax Inc : "I've been saying, 'sell this stock,' the whole way down. Loading chart...Healthpeak Properties Inc : "It just simply isn't as good as Ventas ."

☆ COVID-ситуация в мире: В России зарегистрировали первую вакцину от коронавируса для животных
▼ + stars: | 2021-03-31 | by ( ) novostipmr.com time to read: +6 min

С 12 апреля жители страны смогут свободно передвигаться в пределах своего округа. Также с 12 апреля смогут возобновить работу предприятия строительной отрасли. С 5 апреля начнут работать ясли и детские сады, а с 12 апреля будут восстановлены школьные занятия. Всего на данный момент в России зарегистрировано 4,54 млн случаев заражения коронавирусной инфекцией. В Молдове за последние сутки сделали 4469 тестов и выявили 917 новых случаев коронавируса, в том числе у 29 медиков.

Organizations: East Airlines, AstraZeneca Pfizer, Novavax Inc, —, Университет Джонса Хопкинса, Спутник, Россельхознадзор, Оперштаб, Минздрав Locations: США, Бразилия, Индия, Франция, Россия, Ирландия, Болгария, Ливан, Берлин, Германия, Грузия, Испания, Израиль, ФРГ, Украина, Киев, Одесская, Харьковская, Львовская, Запорожская, Молдова, Приднестровье

Search resuls for: "Novavax Inc"

11 mentions found